• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Envista Holdings Corporation

    8/1/25 4:14:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    S-8 1 nvst-formsx8xaugust2025.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 1, 2025
    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    envistalogoa25a.jpg
    ENVISTA HOLDINGS CORPORATION
    (Exact name of registrant as specified in its charter)
    Delaware83-2206728
    (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
    200 S. Kraemer Blvd., Building E92821-6208
    Brea,California
    (Address of Principal Executive Offices)(Zip Code)
        
    Envista Holdings Corporation 2019 Omnibus Incentive Plan
    (Full title of the Plan)

    Heather L. Turner
    Vice President, Assistant General Counsel, Corporate Securities and Governance
    Envista Holdings Corporation
    200 S. Kraemer Blvd., Building E, Brea, California 92821
    (714) 817-7000
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Copies to:

    Lori B. Metrock
    Maynard Nexsen PC
    1901 Sixth Ave. N, Suite 1700
    Birmingham, AL 35203
    (205) 254-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

        


    Large accelerated filer ☒  Accelerated filer ☐
    Non-accelerated filer ☐  Smaller reporting company ☐
       Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐                                            



        


    EXPLANATORY NOTE

    The purpose of this Registration Statement is to register an additional 6,425,000 shares of common stock of Envista Holdings Corporation (the “Company”) to be issued pursuant to the Envista Holdings Corporation 2019 Omnibus Incentive Plan (as amended to date, the “2019 Plan”).

    The common stock registered hereunder is in addition to the shares of common stock previously registered on the Company’s Registration Statements on Form S-8 filed on September 17, 2019 (Commission File No. 333-233810), February 24, 2022 (Commission File No. 333-262985) and September 19, 2024 (Commission File No. 333-282219).

    This Registration Statement is filed in accordance with General Instruction E to Form S-8, “Registration of Additional Securities.” Pursuant to Instruction E, the contents of the Registration Statements on Form S-8 (Commission File Nos. 333-233810, 333-262985 and 333-282219) are incorporated by reference and made a part of this Registration Statement except to the extent supplemented, amended or superseded by the information set forth herein.
    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in Part I will be sent or given to participants in the 2019 Plan as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). Consistent with the instructions of Part I of Form S-8, such documents will not be filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus as required by Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

        The following documents previously filed by the Company with the Commission are incorporated by reference in this Registration Statement:

    (a)The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 13, 2025;

    (b)The Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 28, 2025 (filed with the Commission on May 1, 2025) and June 27, 2025 (filed with the Commission on July 31, 2025);

    (c)The Company’s Current Reports on Form 8-K filed with the Commission on February 5, 2025, June 12, 2025, and July 16, 2025 (except for portions of such reports which are deemed to be furnished and not filed); and

    (d)The description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A filed with the Commission on September 17, 2019 (File No. 001-39054), including any amendment(s) or report(s) filed for the purpose of updating such description, including Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 13, 2025.


        



    All documents filed by the Company subsequent to the date of this Registration Statement pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents (except, with respect to each of the foregoing, for portions of such documents which are deemed to be furnished and not filed).

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.    Description of Securities.

    Not applicable.

    Item 5.    Interests of Named Experts and Counsel.

        Not applicable.

    Item 6.    Indemnification of Directors and Officers.

    Section 102(b)(7) of the Delaware General Corporation Law (“DGCL”) permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) of a director for unlawful payment of dividends or unlawful stock purchases or redemptions, (iv) for any transaction from which the director or officer derived an improper personal benefit, or (v) of an officer in any action by or in the right of the corporation. Our second amended and restated certificate of incorporation, as amended to date (our “second amended and restated certificate of incorporation”), contains such a provision.

    Section 145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement in connection with specified actions, suits or proceedings, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation - a “derivative action”), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys’ fees) incurred in connection with defense or settlement of such action, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. Our second amended and restated certificate of incorporation and our third amended and restated bylaws contain such a provision.

    We have in effect a directors and officers liability insurance policy indemnifying our directors and officers for certain liabilities incurred by them, including liabilities under the Securities Act, and the Exchange Act. We pay the entire premium of this policy.

        


    We have entered into indemnification agreements with each of our directors and officers that provide for indemnification and advancement of expenses, which rights are in addition to any other rights such directors and officers may be entitled under the Company’s second amended and restated certification of incorporation, third amended and restated bylaws, any other agreement, any vote of stockholders or disinterested directors, the DGCL, or any other law.

    These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the provisions discussed above, the Company has been informed that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

    The foregoing discussion of the Company’s second amended and restated certification of incorporation, third amended and restated bylaws and the DGCL is not intended to be exhaustive and is qualified in its entirety by such second amended and restated certification of incorporation, third amended and restated bylaws and the DGCL, respectively

    Item 7.    Exemption from Registration Claimed.

    Not applicable.

    Item 8.    Exhibits.

    Exhibit No.Description of Exhibit
    4.1
    Second Amended and Restated Certificate of Incorporation of Envista Holdings Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended July 2, 2021, Commission File No. 001-39054).
    4.2
    Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed on May 24, 2024, Commission File No. 001-39054).
    4.3
    Third Amended and Restated Bylaws of Envista Holdings Corporation effective as of May 22, 2023 (incorporated by reference to Exhibit 3.2 to Registrant’s Current Report on Form 8-K filed on May 26, 2023, Commission File No. 001-39054).
    4.4*
    Envista Holdings Corporation 2019 Omnibus Incentive Plan, inclusive of all amendments through June 10, 2025.
    5.1*
    Opinion of Maynard Nexsen PC
    23.1*
    Consent of Ernst & Young LLP.
    23.2*
    Consent of Maynard Nexsen PC. (included in Exhibit 5.1).
    24.1
    Power of Attorney (included on the signature page hereto).
    107.1*
    Filing Fee Table.
    *Filed herewith

    Item 9.    Undertakings.


    (a)    The undersigned registrant hereby undertakes:

    (1)    To file, during any period in which offers or sales are being made, a post-effective
    amendment to this Registration Statement:

    (i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;
        



    (ii)    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement;

    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


        


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Brea, State of California, on August 1, 2025.
                            
      ENVISTA HOLDINGS CORPORATION
      By: /s/ Eric Hammes
       Eric Hammes
       Senior Vice President & Chief Financial Officer


    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul Keel and Eric Hammes, and each of them, with full power of substitution, such person’s true and lawful attorneys-in-fact and agents for such person, with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents determine may be necessary or advisable or required to comply with the Securities Act and any rules or regulations or requirements of the Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that said attorneys and agents shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

        


    SignatureTitleDate
    /s/ Paul Keel
    Paul Keel
    President, Chief Executive Officer
    (Principal Executive Officer) and Director
    August 1, 2025
    /s/ Eric Hammes
    Eric Hammes
    Senior Vice President and Chief Financial Officer
    (Principal Financial Officer)
    August 1, 2025
    /s/ Faez Kaabi
    Faez Kaabi
    Vice President and Chief Accounting Officer
    (Principal Accounting Officer)
    August 1, 2025
    /s/ Scott Huennekens
    Scott Huennekens
    Chairman of the BoardAugust 1, 2025
    /s/ Wendy Carruthers
    Wendy Carruthers
    DirectorAugust 1, 2025
    /s/ Kieran T. Gallahue
    Kieran T. Gallahue
    DirectorAugust 1, 2025
    /s/ Barbara Hulit
    Barbara Hulit
    DirectorAugust 1, 2025
    /s/ Vivek Jain
    Vivek Jain
    DirectorAugust 1, 2025
    /s/ J. Andrew Pierce
    J. Andrew Pierce
    DirectorAugust 1, 2025
    /s/ Daniel A. Raskas
    Daniel A. Raskas
    DirectorAugust 1, 2025
    /s/ Christine Tsingos
    Christine Tsingos
    DirectorAugust 1, 2025

        
    Get the next $NVST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    2/26/2024$19.00Underperform
    Leerink Partners
    2/9/2024$30.00 → $23.00Buy → Hold
    Jefferies
    More analyst ratings

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envista Reports Second Quarter 2025 Results

    BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended June 27, 2025. "Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter," said Paul Keel, CEO. "This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year profitability. Based on the first half momentum and results, we are raising our full year guidance for 2025." Financial Highlights: Q2 2025 highlightsSales were

    7/31/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Second Quarter 2025 Earnings Call

    BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation. You can access the conference call by diali

    7/9/25 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Announces Participation in Stifel 2025 Jaws & Paws Conference

    BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET. A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/.  ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS

    5/22/25 4:15:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Envista upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

    5/27/25 9:05:49 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Mizuho initiated coverage on Envista with a new price target

    Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00

    12/4/24 7:46:09 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously

    10/31/24 6:27:39 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

    SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

    8/14/25 4:20:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Envista Holdings Corporation

    SCHEDULE 13G - Envista Holdings Corp (0001757073) (Subject)

    8/5/25 3:59:29 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Envista Holdings Corporation

    S-8 - Envista Holdings Corp (0001757073) (Filer)

    8/1/25 4:14:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pierce James Andrew was granted 9,155 shares (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    7/16/25 4:17:26 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pierce James Andrew

    3 - Envista Holdings Corp (0001757073) (Issuer)

    7/16/25 4:15:51 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Gallahue Kieran was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    6/12/25 4:55:53 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/14/24 4:40:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/13/24 6:01:10 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    11/20/23 5:49:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Financials

    Live finance-specific insights

    View All

    Envista Reports Second Quarter 2025 Results

    BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended June 27, 2025. "Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter," said Paul Keel, CEO. "This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year profitability. Based on the first half momentum and results, we are raising our full year guidance for 2025." Financial Highlights: Q2 2025 highlightsSales were

    7/31/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Second Quarter 2025 Earnings Call

    BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation. You can access the conference call by diali

    7/9/25 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Reports First Quarter 2025 Results

    BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

    5/1/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Compass Diversified Announces Stephen Keller as Chief Financial Officer

    WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

    8/26/24 6:00:00 AM ET
    $AVY
    $CODI
    $NVST
    Containers/Packaging
    Consumer Discretionary
    Home Furnishings
    Medical/Dental Instruments

    Envista Holdings Corporation Announces Key Leadership Appointments

    BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

    7/15/24 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    2/14/24 4:08:38 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care